Benzoxphosphine ligand and complex and application thereof
By using benzoxoxophosphine ligands in iridium complexes, the problems of cumbersome synthesis and poor diastereoselectivity of oxocyclic phosphine ligands have been solved, realizing a simple and efficient preparation method and a highly enantioselective asymmetric hydrogenation reaction.
Patent Information
- Application Number
- CN202511495819.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-10-17
- Publication Date
- 2026-02-06
AI Technical Summary
Existing methods for synthesizing oxocyclic phosphine ligands are cumbersome, make it difficult to achieve structural diversity, and have poor diastereoselectivity, requiring additional resolution or redox operations.
Chiral phosphine ligands were synthesized directly from readily available chiral aldehydes via tandem nucleophilic addition and intramolecular aromatic nucleophilic substitution reactions using benzoxoxophosphine ligands and iridium complexes. These ligands were then used for the asymmetric hydrogenation of diethyl α-phenylvinyl phosphate.
It achieves a concise synthesis procedure and high enantioselectivity, the preparation method is simple and easy to operate, the catalyst has excellent activity, and it is suitable for asymmetric hydrogenation reactions.
Smart Images

Figure CN121471281A_ABST
Abstract
Description
Technical Field
[0001] This application relates to the field of catalyst ligand technology, and in particular to a benzoxophosphine ligand, its complexes, and applications. Background Technology
[0002] Chiral cyclic phosphine ligands are a class of ligands with significant applications in homogeneous catalysis. Their structural rigidity and excellent air and humidity stability make them outstanding in asymmetric synthesis. Since the development of representative ligands such as BIBOP and BI-DIME by Professor Wenjun Tang's group, chiral cyclic phosphine ligands such as iBu-OxaPhos, WingPhos, and LalithPhos have been widely used in key reactions such as cross-coupling and asymmetric hydrogenation. However, the synthesis of these ligands still faces many challenges. Representative oxocyclic phosphine ligands are as follows:
[0003] Traditional synthetic methods primarily rely on linear, multi-step reactions, obtaining optically pure products through the resolution of phosphine oxide intermediates. This inevitably involves redox steps, which are not only cumbersome but also limit scalability and cost-effectiveness. Another strategy involves the condensation reaction of chiral secondary phosphines with ketals, but this method often suffers from poor diastereoselectivity, requiring additional resolution or redox operations to obtain optically pure ligands. Furthermore, existing methods are mostly limited to single-phosphine or C2-symmetric bisphosphine structures, making it difficult to achieve modular construction of structurally diverse oxacyclic phosphine ligands. Existing synthetic strategies for oxacyclic phosphine ligands and their characteristics are as follows:
[0004] Therefore, developing new, efficient, and modular strategies for synthesizing chiral oxocyclic phosphine ligands has significant research and application value. Summary of the Invention
[0005] The purpose of this application is to provide a novel benzoxophosphine ligand, its complexes, and its applications.
[0006] To achieve the above objectives, this application adopts the following technical solution: One aspect of this application discloses a benzoxophosphine ligand with the structure shown in formula (I). Formula (I) ; Wherein, R1 is an alkyl or aryl-substituted oxazolyl or imidazoline, R2 is an alkyl and / or aryl group, and R3 is at least one of fluorine, carbazole and 2,6-dimethoxyphenyl.
[0007] It should be noted that this application develops a novel chiral benzoxophosphine ligand with a ferrocene framework. Its iridium metal complex can be used as a catalyst in the asymmetric hydrogenation reaction of diethyl α-phenylvinyl phosphate, exhibiting excellent activity and high enantioselectivity. More importantly, the preparation steps of the chiral benzoxophosphine ligand in this application are concise, directly synthesized from readily available chiral aldehydes; avoiding lengthy linear synthesis steps and poor diastereoselectivity.
[0008] In one implementation of this application, R1 is selected from any of the following structures. .
[0009] In one implementation of this application, R2 is selected from any of the following structures. .
[0010] In one implementation of this application, in formula (I), Choose from any of the following structures, .
[0011] In one implementation of this application, the compound represented by formula (I) has any of the following structures. .
[0012] It should be noted that the 12 specific structural formulas of benzoxophosphine ligands mentioned above are only 12 benzoxophosphine ligands specifically synthesized in one implementation of this application. It is understood that, under the inventive concept of this application, more chiral phosphine ligands containing a ferrocene framework can be synthesized, not limited to the above 12.
[0013] Another aspect of this application discloses a complex formed by the benzoxophosphine ligand of this application and metallic iridium.
[0014] It should be noted that the complexes of this application, namely metal Ir complexes, possess excellent activity and high enantioselectivity due to the use of the benzoxophosphine ligands of this application.
[0015] Another aspect of this application discloses the use of the complex of this application in the preparation of catalysts for enantioselective asymmetric hydrogenation reactions.
[0016] Another aspect of this application discloses a method for enantioselective asymmetric hydrogenation, comprising using the complex of this application as a catalyst to catalyze the asymmetric hydrogenation reaction.
[0017] In one implementation of this application, the asymmetric hydrogenation reaction is carried out under organic solvent and hydrogen pressure conditions to achieve the asymmetric hydrogenation of α-phenylvinyl phosphate diethyl ester.
[0018] In one implementation of this application, the reaction formula for the asymmetric hydrogenation reaction of α-phenylvinyl phosphate diethyl ligand [Ir(COD)Cl]2 under organic solvent and hydrogen pressure conditions is as follows: .
[0019] In one implementation of this application, the solvent is at least one selected from N,N-dimethylformamide, toluene, trifluorotoluene, carbon tetrachloride, dioxane, hexafluoroisopropanol, ethyl acetate, and dichloromethane.
[0020] It should be noted that the key to the asymmetric hydrogenation reaction of this application lies in using the complex of this application as a catalyst, namely the complex formed by the complexation of the benzoxophosphine ligand of this application with metallic iridium; therefore, it has advantages such as good reactivity and strong enantioselectivity. As for the other steps and conditions of the asymmetric hydrogenation reaction, existing enantioselective asymmetric hydrogenation methods can be referred to, and will not be elaborated here.
[0021] Due to the adoption of the above technical solutions, the beneficial effects of this application are as follows: The benzoxophosphine ligand of this application has an iridium metal complex that can be used as a catalyst in the asymmetric hydrogenation reaction of α-phenylvinyl phosphate, exhibiting excellent activity and high enantioselectivity. Furthermore, the benzoxophosphine ligand of this application can be directly synthesized from readily available chiral aldehydes, and the preparation method is simple and easy to operate. Attached Figure Description
[0022] Figure 1 This is the hydrogen nuclear magnetic resonance image of ligand 1 in the embodiments of this application; Figure 2 This is the carbon nuclear magnetic resonance image of ligand 1 in the embodiments of this application; Figure 3 This is the phosphorus nuclear magnetic resonance image of ligand 1 in the embodiments of this application; Figure 4 This is the hydrogen nuclear magnetic resonance image of ligand 2 in the embodiments of this application; Figure 5 This is the carbon nuclear magnetic resonance image of ligand 2 in the embodiments of this application; Figure 6 This is the phosphorus nuclear magnetic resonance image of ligand 2 in the embodiments of this application; Figure 7 This is the hydrogen nuclear magnetic resonance image of product 14 in the embodiments of this application; Figure 8 This is the carbon nuclear magnetic resonance image of product 14 in the embodiments of this application; Figure 9 This is the phosphorus nuclear magnetic resonance image of product 14 in the embodiments of this application. Detailed Implementation
[0023] The present invention will now be described in further detail with reference to specific embodiments and accompanying drawings. In the following embodiments, many details are described to facilitate a better understanding of the present application. However, those skilled in the art will readily recognize that some features may be omitted in different situations, or may be replaced by other materials or methods. In some cases, certain operations related to the present application are not shown or described in the specification. This is to avoid obscuring the core parts of the present application with excessive description. For those skilled in the art, detailed description of these related operations is not necessary; the relevant operations can be fully understood based on the description in the specification and general technical knowledge in the art.
[0024] The serial numbers assigned to structural formulas or functional groups in this application, such as “Formula (I)”, “Ligand 1”, “Ligand 2”, “Ligand 12”, “R1”, “R2”, “R3”, etc., are used only to distinguish the described objects and have no sequential or technical meaning.
[0025] Terminology Explanation: In this application, Pr represents propyl, Bu represents butyl, Ph represents phenyl, Cy represents cyclohexyl, Ad represents adamantyl, Me represents methyl, THP represents tetrahydropyranyl, and Ar represents aryl.
[0026] This application develops a modular synthesis strategy based on "phosphine click reagents," which achieves efficient construction of chiral phosphine nitrogen ligands through tandem nucleophilic addition and intramolecular aromatic nucleophilic substitution reactions. Furthermore, it realizes asymmetric hydrogenation reactions mediated by iridium complexes of some chiral phosphine nitrogen ligands.
[0027] The benzoxophosphine ligand of this application has the structure shown in formula (I). Formula (I) ; Wherein, R1 is alkyl and / or aryl, R2 is alkyl and / or aryl, and R3 is at least one of fluorine, carbazole and 2,6-dimethoxyphenyl.
[0028] This application develops a series of chiral phosphine ligands containing a ferrocene framework, which, when applied to the asymmetric hydrogenation of diethyl α-phenylvinyl phosphate, have the following advantages compared to existing technologies: (1) The preparation steps of the benzoxophosphine ligand in this application are short and can be directly synthesized from readily available chiral aldehydes; avoiding the long linear synthesis steps and poor diastereoselectivity.
[0029] (2) The asymmetric applications of the benzoxophosphine ligands provided in this application specifically provide successful application examples of them in the asymmetric hydrogenation of α-phenylvinyl phosphate, which have excellent activity and high enantioselectivity. Example
[0030] The synthesis process of the benzoxophosphine ligand in this example is as follows:
[0031] Specifically, under an argon atmosphere at room temperature, the corresponding substrate phosphine 15 (0.2 mmol, 66.3 mg) was dissolved in 2 mL of dry tetrahydrofuran. Potassium tert-butoxide solid (0.3 mmol, 1.5 equiv.) (Biode, BD148904) and the corresponding chiral aldehyde 16 (0.3 mmol, 97.6 mg) were added sequentially, and the reaction was stirred until TLC analysis showed complete consumption of the starting material. Purification was performed by column chromatography using degassed petroleum ether-ethyl acetate (20:1–5:1) as the eluent, yielding a diastereoselectivity greater than 20:1 to obtain an orange-yellow solid 1 (102.1 mg, 78% yield, >20:1 dr), labeled as ligand 1.
[0032] The hydrogen nuclear magnetic resonance image of product 1, i.e., ligand 1, is shown below. Figure 1 As shown, the carbon NMR spectrum is as follows: Figure 2 As shown, the phosphorus nuclear magnetic resonance image is as follows: Figure 3 As shown, the structural characterization data of product 1 are as follows: Orange solid, 102.1 mg, 78% yield, >20:1 dr. 1H NMR (400 MHz, CDCl3) δ(ppm) 8.1 (d, J = 7.7 Hz, 1H), 8.0 – 8.0 (m, 1H), 7.5 (t, J = 7.9 Hz, 1H),7.4 (d, J = 8.1 Hz, 1H), 7.4 (t, J = 7.5 Hz, 1H), 7.3 – 7.1 (m, 4H), 7.1 (dd,J = 7.7, 2.5 Hz, 1H), 7.0 (d, J = 3.7 Hz, 1H), 6.7 (s, 1H), 4.7 (s, 1H), 4.3(d, J = 7.3 Hz, 6H), 4.2 (t, J = 8.9 Hz, 1H), 4.1 (s, 1H), 4.0 (t, J = 7.9Hz, 1H), 3.9 (dt, J = 9.2, 7.2 Hz, 1H), 1.0 (d, J = 6.7 Hz, 3H), 0.9 (d, J =6.7 Hz, 3H), 0.7 (d, J = 12.3 Hz, 9H). 13 C NMR (150 MHz, CDCl3) δ (ppm) 166.2,165.0, 141.3 (d, J = 13.5 Hz), 141.0, 139.2, 132.4, 125.6 (d, J = 3.8 Hz),123.6, 123.1, 122.4, 122.1, 120.3 (d, J = 2.4 Hz), 120.1, 119.9, 119.7, 111.8(d, J = 8.3 Hz), 110.3, 109.7, 90.2 (d, J = 26.9 Hz), 80.9 (d, J = 26.3 Hz),72.4, 70.5, 69.8, 69.3, 68.7, 67.9, 66.9, 32.7, 32.1 (d, J = 23.0 Hz), 27.0(d, J = 14.5 Hz), 18.7 (d, J = 29.7 Hz). 31 P NMR (162 MHz, CDCl3) δ (ppm)12.27. HRMS (ESI-TOF) m / z: [M+H]+ Calcd for C39H40FeN2O2P+ = 655.2171; Found655.2170。
[0033] The preparation process of the substrate phosphine hydrogen 15 used in this example is as follows:
[0034] Specifically, it includes: Under argon protection, n-butyllithium (10 mmol, 1.0 eq.) was slowly added dropwise to a 20 mL anhydrous THF solution of substrate 17 (3.4 g, 10 mmol, 1.0 eq.) (catalog number: BD01880) at -78 °C, and the mixture was stirred at this temperature for 2 hours. Subsequently, a 2 mL anhydrous THF solution of tert-butyldichlorophosphine (1.6 g, 10 mmol, 1.0 eq.) (catalog number: BD152469) was rapidly added to the above reaction mixture at -78 °C, and the mixture was stirred at -78 °C for another 2 hours. Next, LiAlH4 (20 mmol, 2.0 eq., 1.0 M THF solution) was slowly added dropwise to the mixture at -78 °C. After the addition was complete, the reaction mixture was gradually heated to room temperature and stirred for another 4 hours. After the reaction was complete, the reaction was quenched with degassed H₂O (0.2 mL) under ice-water bath conditions. Volatile solvents were removed using anhydrous and oxygen-free techniques, and the residue was diluted with degassed n-hexane (50 mL). Subsequently, the mixture was filtered through a diatomaceous earth mat under an argon atmosphere, and the filter cake was washed with degassed n-hexane (100 mL). All filtrates were collected and combined, and the solvent was removed under vacuum using anhydrous and oxygen-free techniques to obtain the corresponding phosphine product, substrate phosphine 15, as a pale yellow solid weighing 2.2 g, with a yield of 63%.
[0035] Characterization data of substrate phosphine hydrogen 15: 1 H NMR (600 MHz, CDCl3) δ (ppm) 7.94 (d, J = 7.7 Hz, 2H), 7.24-7.17(m, 3H), 7.09 (q, J = 6.9 Hz, 2H), 7.03 (t, J = 8.8 Hz, 2H), 6.99 (d, J = 7.8Hz, 1H), 6.84 (d, J = 8.1 Hz, 1H), 3.44 (dd, J = 223.6, 8.0 Hz, 1H), 0.72 (d,J = 12.7 Hz, 9H). 13C NMR (150 MHz, CDCl3) δ (ppm) 165.0 (dd, J = 245.0, 9.0Hz), 141.9 (dd, J = 7.3, 4.7 Hz), 141.8 , 141.1 , 130.9 (d, J = 10.3 Hz), 125.9 (d, J = 39.7 Hz), 125.1 (d, J = 2.9 Hz), 124.04- 123.41 (m), 123.2 (d,J = 12.1 Hz), 120.2 (d, J = 15.7 Hz), 120.0 (d, J = 4.5 Hz), 115.2 (d, J =25.4 Hz), 110.6 (d, J = 1.8 Hz), 110.1, 77.2, 77.0, 76.8, 30.4 (d, J = 12.7Hz), 30.2 (d, J = 12.0 Hz). 19 F NMR (376 MHz, CDCl3) δ (ppm) -95.17. 31 P NMR(162 MHz, CDCl3) δ (ppm) -49.25 (d, J = 23.1 Hz). HRMS (ESI-TOF) m / z: [M+H]+Calcd for C22H22FNP+ = 350.3966; Found 350.3968. The preparation process of chiral aldehyde 16 used in this example is as follows:
[0036] To a solution of substrate 18, i.e., (S)-(4-isopropyl-2-oxazoline-2-yl)ferrocene (3.0 g, 10.1 mmol, 1.0 eq.) (catalog number: Bailingwei 255989), n-butyllithium (14.0 mL, 14.1 mmol, 1.4 eq.) was added. The mixture was cooled to -78 °C and reacted at -78 °C for 2 hours. The reaction mixture was then warmed to 0 °C. The mixture was stirred for 5 minutes. The reaction was quenched with dry N,N-dimethylformamide (0.94 mL, 12.1 mmol, 1.2 eq.). The reaction mixture was allowed to warm naturally to room temperature. The reaction was then quenched with water (20 mL). The organic phase was washed with saturated brine. The organic phase was then dried over anhydrous magnesium sulfate. The organic phase was filtered and concentrated under reduced pressure to give a red, viscous oil. The red, viscous oil was purified by rapid chromatography (n-hexane:ethyl acetate = 4:1) to give the product, chiral aldehyde 16 (2.7 g, 83% yield).
[0037] Characterization data of chiral aldehyde 16: 1 H NMR (400 MHz, CDCl3) δ (ppm) 0.98 (d, 3H, J = 6.6 Hz), 1.03 (d,3H, J = 6.6 Hz), 1.83 (oct, 1H, J = 6.6 Hz), 3.9-4.4 (m, 3H), 4.29 (s, 5H), 4.73 (s, 1H), 5.04 (s, 1H), 5.09 (s, 1H), 10.71 (s, 1H). 13 C NMR (150 MHz, CDCl3) δ (ppm) 18.1, 18.8, 32.5, 69.7, 69.9, 71.4, 72.4, 73.1, 73.2, 74.5,78.8, 163.9, 195.6. Using the same method, ligand 2 was prepared in this example using phosphine hydrogen 15 and 19 as substrates. Specifically, potassium tert-butoxide solid (Biode, BD148904) and substrate phosphine hydrogen 15 were added sequentially to dry tetrahydrofuran, followed by the addition of 19. This example synthesized ligand 2, whose structural formula is as follows:
[0038] The hydrogen NMR spectrum of ligand 2 is shown below. Figure 4 As shown, the carbon NMR spectrum is as follows: Figure 5As shown, the phosphorus nuclear magnetic resonance image is as follows: Figure 6 As shown, the structural characterization data of ligand 2 are as follows: Orange solid, 97.6 mg, 73% yield, >20:1 dr. 1 H NMR (400 MHz, CDCl3) δ (ppm)8.1 (d, J = 7.7 Hz, 1H), 8.0 (dq, J = 6.8, 3.8 Hz, 1H), 7.5 (t, J = 7.9 Hz,1H), 7.4 (d, J = 8.2 Hz, 1H), 7.4 (t, J = 7.6 Hz, 1H), 7.3 – 7.1 (m, 4H), 7.1 – 7.0 (m, 2H), 6.8 (s, 1H), 4.7 (s, 1H), 4.4 – 4.3 (m, 6H), 4.2 – 4.1 (m,1H), 4.1 – 4.0 (m, 2H), 3.8 (dd, J = 10.0, 7.8 Hz, 1H), 1.0 (s, 9H), 0.7 (d,J = 12.4 Hz, 9H). 13 C NMR (150 MHz, CDCl3) δ (ppm) 166.2, 141.3 (d, J = 13.2Hz), 141.0, 139.2, 132.5, 125.6, 123.6, 123.2, 122.4, 122.1, 120.3 (d, J =2.5 Hz), 120.1, 119.9, 119.7, 111.9 (d, J = 8.1 Hz), 110.3, 109. , 90.3 (d, J= 26.8 Hz), 80.6 (d, J = 26.5 Hz), 76.3, 70.4, 69.8, 68.7, 67.6, 66.8, 34.7,33.4, 32.0 (d, J = 22.6 Hz), 27.0 (d, J = 14.7 Hz), 26.1. 31 P NMR (162 MHz, CDCl3) δ (ppm) 12.67. HRMS (ESI-TOF) m / z: [M+Na]+ Calcd for C40H41FeN2NaO2P+= 691.2147; Found 691.2153.
[0039] The preparation process of 19 is as follows:
[0040] To a solution of substrate 20, i.e., (S)-(5-tert-butyloxazolidinyl)ferrocene (3.5 g, 10.1 mmol, 1.0 eq.) (catalog number: BD01186020), in a mixture of dry diethyl ether (200 mL) and tetramethylethylenediamine (2.1 mL, 14.1 mmol, 1.4 eq.) (catalog number: Bailingwei 255989), n-butyllithium (14.0 mL, 14.1 mmol, 1.4 eq.) was added. The mixture was cooled to -78 °C and reacted at -78 °C for 2 hours. The reaction mixture was then warmed from this temperature to 0 °C. The mixture was stirred for 5 minutes. The reaction was quenched with dry N,N-dimethylformamide (0.94 mL, 12.1 mmol, 1.2 eq.). The reaction mixture was allowed to warm naturally to room temperature. The reaction was then quenched with water (20 mL). The organic phase was washed with saturated brine. The organic phase was then dried over anhydrous magnesium sulfate. The organic phase was filtered and concentrated under reduced pressure to give a red, viscous oil. The red, viscous oil was purified by rapid chromatography (n-hexane:ethyl acetate = 4:1) to give 19 (2.9 g, 85% yield).
[0041] Characterization data for 19: 1 H NMR (400 MHz, CDCl3) δ (ppm) 0.99 (s, 9H), 3.97 (dd, 1H, J = 7.5,10.0 Hz), 4.15-4.25 (m, 2H), 4.29 (s, 5H), 4.72 (t, 1H, J = 2.7 Hz), 5.00 (d,1H, J = 1.0 Hz), 5.09 (s, 1H), 10.74 (s, 1H). 13 C NMR (150 MHz, CDCl3) δ (ppm) 25.8, 33.5, 68.0, 70.0, 71.1, 72.9, 73.6, 74.7, 76.5, 78.6, 163.5, 195.1. Example 2 Enantioselective hydrogenation reaction (14) The chiral benzoxophosphine ligand prepared in Example 1 was applied to the iridium-catalyzed asymmetric hydrogenation reaction of α-arylvinylphosphonate as follows:
[0042] In an argon-filled glove box, a 10 mL reaction tube, dried in an oven, was loaded with [Ir(COD)Cl]₂ (33.6 mg, 0.05 mmol) (Annegi, 12112-67-3), ligand 1 (65.5 mg, 0.10 mmol), and NaBArF (88.6 mg, 0.10 mmol) (Bide, BD151653), and anhydrous dichloromethane (2.0 mL) was added. The mixture was heated to 35 °C and stirred at this temperature for 30 minutes. The reaction system was then cooled to room temperature, and the crude product was purified by column chromatography (petroleum ether / dichloromethane = 1:1) to give an orange oily iridium complex (43.6 mg, yield 24%). The iridium complex was dissolved in dichloromethane to prepare a 0.02 M solution for later use.
[0043] In an argon-protected glove box, substrate 13 (24 mg, 0.1 mmol) and anhydrous dichloromethane (0.9 mL) were added to an oven-dried 4 mL open ampoule, followed by the above iridium complex solution (100 μL). The ampoule was transferred to an autoclave, and the reaction system was purged with hydrogen (5 bar) (repeated three times), finally adjusting the hydrogen pressure to 10 bar. The reaction mixture was stirred at room temperature for 48 hours. After the reaction was complete, hydrogen was slowly released, and the solvent was removed by rotary evaporation under reduced pressure. The crude product was purified by column chromatography (eluting with a gradient of petroleum ether / ethyl acetate from 1:1 to 1:10) to give a colorless oily product 14 (23.0 mg, 95% yield). The enantiomeric ratio was determined to be 96.9:3.1 by chiral HPLC analysis.
[0044] Product 14 is named (S)-1-phenylethylphosphonic acid diethyl ester, and its structural formula is as follows:
[0045] The hydrogen NMR spectrum of product 14 is shown below. Figure 7 As shown, the carbon NMR spectrum is as follows: Figure 8 As shown, the phosphorus nuclear magnetic resonance image is as follows: Figure 9 As shown, the structural characterization data of product 14 are as follows: A colorless, oily liquid, 23.0 mg, 95% yield. The enantiomeric ratio was established as 96.9:3.1 by chiral HPLC analysis with a Daicel Chiralpak AD-H column (n-hexane:iPrOH = 97:3, 1.0 mL / min), λ = 210 nm, temperature = 28 °C, tr (major) = 11.276 min, tr (minor) = 13.916 min. [α]D20 = -6.9 (1.0, CHCl3). 1 H NMR(400 MHz, CDCl3) δ (ppm) 7.38 – 7.29 (m, 4H), 7.28 – 7.21 (m, 1H), 4.08-3.97(m, 2H), 3.97 – 3.87 (m, 1H), 3.86 – 3.73 (m, 1H), 3.18 (dq, J = 22.4, 7.4Hz, 1H), 1.58 (dd, J = 18.5, 7.4 Hz, 3H), 1.27 (t, J = 7.1 Hz, 3H), 1.14 (t,J = 7.1 Hz, 3H). 13 C NMR (100 MHz, CDCl3) δ (ppm) 137.9 (d, J = 7.1 Hz), 128.6 (d, J = 6.5 Hz), 128.4 (d, J = 2.8 Hz), 127.0 (d, J = 3.5 Hz), 62.4 (d, J =7.2 Hz), 61.9 (d, J = 7.2 Hz), 38.4 (d, J = 137.7 Hz), 16.4 (d, J = 5.9 Hz), 16.2 (d, J = 5.8 Hz), 15.5 (d, J = 5.1 Hz). 31 P NMR (162 MHz, CDCl3) δ (ppm) 29.80.
[0046] The preparation process of substrate 13 is as follows:
[0047] Add 1.0 mL of reactant 21 (1 g, 8.6 mmol) and 1.55 mL of reactant 22 (16.6 mmol) sequentially to a Schlenk tube. Stir the solution at room temperature and add 2.1 mL of Tf₂O (12.5 mmol) dropwise over approximately 20 minutes. Add 1.0 mL of pyridine (12.5 mmol) five times to the stirred solution. Stir the reaction at 35°C for approximately 6 hours. After the reaction is complete, add 100 mL of ethyl acetate and 100 mL of saturated sodium bicarbonate solution to the solution and stir for approximately half an hour. Separate the organic layer, and extract the aqueous phase with ethyl acetate (3 × 30 mL). Combine the organic phases, dry over anhydrous sodium sulfate, and concentrate under vacuum to remove the solvent. Purify the residue by column chromatography (using petroleum ether:ethyl acetate = 1:1 as eluent). Substrate 13 (1.9 g, 93% yield) is given.
[0048] Characterization data of substrate 13: 1 H NMR (400 MHz, CDCl3) δ (ppm) 7.53 (d, J = 3 Hz 2H), 7.37-7.31 (m,3H), 6.34 (dd, J = 22 Hz, 1 Hz, 1H), 6.16 (dd, J = 46 Hz, 1 Hz, 1H), 4.16-4.05(m, 4H),1.28 (t, 6H) 13 C NMR (150 MHz, CDCl3) δ (ppm) 139.8 (d, J = 173.5Hz), 136.7 (d, J = 11.88 Hz), 131.7(d, J = 8 Hz), 128.4, 128.2, 127.5 (d, J =5.63Hz), 62.2(d, J = 5 Hz), 16.2(d, J = 6.2 Hz).
[0049] The above description, in conjunction with specific embodiments, provides a further detailed explanation of this application and should not be construed as limiting the specific implementation of this application to these descriptions. Those skilled in the art to which this application pertains can make several simple deductions or substitutions without departing from the concept of this application.
Claims
1. A benzo-oxazaphosphin ligand characterized in that: The structure is shown as formula (I), Formula (I) ; wherein R1 is alkyl or aryl-substituted oxazolidinyl or imidazoline, R2 is alkyl and / or aryl, and R3 is at least one of fluorine, carbazolyl and 2,6-dimethoxyphenyl.
2. The benzoxaphosphole ligand of claim 1, wherein: R1 is selected from any one of the following structures, 。 3. The benzoxaphosphole ligand of claim 1, wherein: R2 is selected from any one of the following structures, 。 4. The benzoxaphosphole ligand of claim 1, wherein: in formula (I), selected from any one of the following structures, 。 5. The benzoxaphosphole ligand of claim 1, wherein: the compound shown as formula (I) is any one of the following structures, 。 6. A complex of the phenoxazoline ligand of any one of claims 1-5 and metal iridium.
7. Use of the complex of claim 6 in preparing a catalyst for enantioselective asymmetric hydrogenation reaction.
8. A process for the enantioselective asymmetric hydrogenation, characterized in that: The asymmetric hydrogenation reaction is catalyzed by using the complex of claim 6 as a catalyst.
9. The method of claim 8, wherein: The asymmetric hydrogenation reaction is carried out under the conditions of organic solvent and hydrogen pressure to realize asymmetric hydrogenation of diethyl α-phenylvinylphosphonate.
10. The method of claim 9, wherein: The solvent is at least one of N,N-dimethylformamide, toluene, trifluorotoluene, carbon tetrachloride, dioxane, hexafluoroisopropanol, ethyl acetate and dichloromethane.
